Jackpharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Jackpharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Jackpharma Inc Today - Breaking & Trending Today
Molnupiravir (Photo courtesy of Merck & Co.) MANILA - The yet-to-be-approved anti-viral pill molnupiravir still lacks emergency use authorization and no suggested retail price can be issued since it is still under study by regulators, a health official said Friday. In an online media forum, Department of Health (DOH) Undersecretary Maria Rosario Vergeire noted that only four hospitals had been granted compassionate special permit (CSP)to administer the pill that is deemed to cut the risk of hospitalization for adults with mild to moderate symptoms of the coronavirus disease 2019 (Covid-19). Physicians and hospitals using molnupiravir under CSP are accountable for its outcome on the Covid-19 patients. "Having said that, hindi pa rin tayo pwede makapag-issue ng SRP (suggested retail price) kasi pinag-aaralan pa ito (we cannot suggest an SRP because it is still under study)," Vergeire said. "Kelangan lumabas muna ito sa Living CPG Guidelines (Clinical Practice Guideline ....
Molnupiravir importer to 'explore possibility' of producing anti-COVID-19 drug locally cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.
Molnupiravir importer to 'explore possibility' of producing anti-COVID-19 drug locally cnnphilippines.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnnphilippines.com Daily Mail and Mail on Sunday newspapers.
US drugmaker Merck & Co on October 27 announced a deal that could see generic versions of its Covid-19 medication widely distributed in poorer countries, in a first during the pandemic. ....